The U.S. Regulations for Biotechnology Are Woefully Out of Date
By Brooke Borel,
Slate
| 04. 21. 2017
But revamping the way we look at products created by genetic engineering and CRISPR is more difficult than you might think.
In April 2016, an unlikely thing made headlines: the common white button mushroom.
“Gene-Edited CRISPR Mushroom Escapes US Regulation,” wrote Nature.
“What’s a GMO? Apparently Not These Magic Mushrooms,” wrote Grist.
And from MIT Technology Review: “Who Approved the Genetically Engineered Foods Coming to Your Plate? No One.”
The white button mushroom in question looked like any other in the grocery store, with one imperceptible difference: It was missing a gene that codes for an enzyme called PPO, or polyphenol oxidase, which makes mushrooms turn brown when they’re bruised or cut. Scientists at Pennsylvania State University essentially turned off this PPO gene—one of six in the mushroom—with a new gene-editing tool called CRISPR, or clustered regularly interspaced short palindromic repeats. CRISPR is a bit like a biological word processor. It zooms to a specific genetic sequence in any living thing—the biotech equivalent of using Ctrl+F. Then, the tool can add, delete, or replace genetic information...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...